View Financial HealthCoya Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Coya Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-20.5%자사주 매입 수익률총 주주 수익률-20.5%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesHigh number of new directors May 01Coya Therapeutics, Inc. Announces Board ChangesApr 02Consensus revenue estimates increase by 14%, EPS downgraded Mar 23New minor risk - Market cap size Mar 22Coya Therapeutics, Inc. Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia Supporting Mechanistic Rationale for Coya 302 Immune-Restoring TherapyMar 19New major risk - Shareholder dilution Feb 04Coya Therapeutics, Inc. announced that it expects to receive $11.099999 million in funding from Greenlight Capital, Inc., Dr. Reddy's Laboratories Inc.Jan 31New minor risk - Market cap size Jan 13Coya Therapeutics, Inc. Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia PatientsJan 08Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal DementiaJan 06Coya Therapeutics Announces Patients Have Been Dosed in the Alstars Trial of Coya 302 for the Treatment of AlsDec 10Consensus revenue estimates increase by 22% Nov 26Consensus EPS estimates upgraded to US$1.28 loss Nov 19New minor risk - Shareholder dilution Nov 17Coya Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $20.000002 million.Oct 24+ 1 more updateCoya Therapeutics, Inc. Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal DementiaSep 30Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral SclerosisSep 23Coya Therapeutics' COYA 303 Shows Promising Central Nervous System Anti-Inflammatory Effects and Systemic Regulatory T Cell Enhancing Effects in a Preclinical Animal Inflammation ModelSep 17Is Coya Therapeutics (NASDAQ:COYA) In A Good Position To Invest In Growth?Sep 16Coya Therapeutics' Coya 302 Als Trial Accepted by Neals as A Neals-Affiliated TrialSep 05Consensus revenue estimates increase by 478% Aug 26Coya Therapeutics, Inc. Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Aug 26Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 13Coya Therapeutics, Inc. Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's DiseaseJul 24New major risk - Revenue and earnings growth Jul 09Coya Therapeutics Inc. Provides Additional Non-Clinical Data to Support the Initiation of A Planned Clinical Study Entitles Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Open Label ExtensionJul 02Price target increased by 8.1% to US$16.75 Jun 13Coya Therapeutics, Inc., Annual General Meeting, Jun 26, 2025May 19First quarter 2025 earnings: EPS and revenues miss analyst expectations May 14Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal DementiaApr 24Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)Apr 22New minor risk - Market cap size Apr 06We Think Coya Therapeutics (NASDAQ:COYA) Can Afford To Drive Business GrowthApr 04Coya Therapeutics, Inc. Reports Progress from Academic Supported First-in-Class Treg-Derived Exosome ProgramMar 26Consensus EPS estimates upgraded to US$1.01 loss Mar 25New minor risk - Shareholder dilution Mar 23Coya Therapeutics, Inc. Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical DevelopmentFeb 07Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory DiseasesJan 22Coya Therapeutics, Inc. Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (Ld Il-2) + Ctla4-Ig Fusion Protein in Patients with Frontotemporal Dementia (Ftd)Dec 18New minor risk - Market cap size Nov 17Consensus revenue estimates decrease by 27%, EPS upgraded Nov 13Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)Oct 29Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In GrowthOct 29Coya Therapeutics, Inc. announced that it expects to receive $10.000027 million in fundingOct 23Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts Oct 13Consensus EPS estimates fall by 10% Aug 20New minor risk - Share price stability Aug 20Coya Therapeutics, Inc. Announces CEO Changes, Effective November 1, 2024Aug 19Consensus revenue estimates fall by 24% Aug 19Coya Therapeutics, Inc. Submits an Investigational New Drug ApplicationJul 15Consensus revenue estimates fall by 44% Jun 16Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's DiseaseMay 23Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery FoundationMay 22New major risk - Shareholder dilution May 21Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery FoundationMay 21Consensus revenue estimates increase by 64%, EPS downgraded May 16Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024Mar 29Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth PlansMar 26Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology ConferenceMar 13Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal Feb 13Consensus revenue estimates increase by 100% Feb 02Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral SclerosisJan 17Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position Jan 13Coya Therapeutics, Inc. Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of Coya 302 for Treatment of Amyotrophic Lateral SclerosisJan 05Coya Therapeutics, Inc. announced that it has received $26.484515 million in fundingDec 14Wilbur Ross Joins Coya Therapeutics' BoardDec 08Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in fundingDec 07Coya Therapeutics, Inc. Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)Oct 10Coya Therapeutics, Inc. Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral SclerosisOct 06New minor risk - Share price stability Oct 05Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium MeetingOct 05Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple DiseasesSep 08We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth CarefullySep 06Coya Therapeutics, Inc. Reports the Publication of a Research Article Entitled “Immunological, Oxidative, and Structural Factors and Their Responses T Lymphocyte Therapy in Amyotrophic Lateral Sclerosis”Sep 01Coya Therapeutics, Inc. Appoints Dieter Weinand to Its Board of DirectorsAug 22New major risk - Financial position Aug 09Coya Therapeutics, Inc. Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical AdvisorJul 22Coya Therapeutics Reports Additional Proof-Of-Concept Clinical Biomarker Data in Patients with Alzheimer's DiseaseJul 18Coya Therapeutics, Inc. Announces Management Changes, Effective July 17, 2023Jul 06Coya Therapeutics, Inc. to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD)Jun 29Coya Therapeutics, Inc. Appoints Dr. Michelle Frazier as Senior Vice President of Regulatory AffairsJun 15Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer's Disease (AD)Jun 08Coya Therapeutics, Inc. Announces Appointment of Dr. Guillaume Dorothée to Scientific Advisory BoardJun 06Coya Therapeutics, Inc., Annual General Meeting, Jun 28, 2023May 20Coya Therapeutics, Inc. Reports Results from an Open-Label Proof-Of-Concept Clinical Study for COYA 301 in patients with AD. Results of the studyMay 17Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn SituationMay 17Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)Jan 28Coya Therapeutics, Inc. has completed an IPO.Dec 31High number of new and inexperienced directors Dec 31지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 COYA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: COYA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Coya Therapeutics 배당 수익률 vs 시장COYA의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (COYA)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.6%분석가 예측 (COYA) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 COYA 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 COYA 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 COYA 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: COYA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/01 06:51종가2026/05/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Coya Therapeutics, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Thomas ShraderBTIGKeay NakaeChardan Capital Markets, LLCJason KolbertD. Boral Capital LLC.5명의 분석가 더 보기
Coya Therapeutics, Inc. Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia Supporting Mechanistic Rationale for Coya 302 Immune-Restoring TherapyMar 19
Coya Therapeutics, Inc. announced that it expects to receive $11.099999 million in funding from Greenlight Capital, Inc., Dr. Reddy's Laboratories Inc.Jan 31
Coya Therapeutics, Inc. Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia PatientsJan 08
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal DementiaJan 06
Coya Therapeutics Announces Patients Have Been Dosed in the Alstars Trial of Coya 302 for the Treatment of AlsDec 10
Coya Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $20.000002 million.Oct 24+ 1 more update
Coya Therapeutics, Inc. Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal DementiaSep 30
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral SclerosisSep 23
Coya Therapeutics' COYA 303 Shows Promising Central Nervous System Anti-Inflammatory Effects and Systemic Regulatory T Cell Enhancing Effects in a Preclinical Animal Inflammation ModelSep 17
Coya Therapeutics, Inc. Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Aug 26
Coya Therapeutics, Inc. Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's DiseaseJul 24
Coya Therapeutics Inc. Provides Additional Non-Clinical Data to Support the Initiation of A Planned Clinical Study Entitles Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Open Label ExtensionJul 02
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal DementiaApr 24
Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)Apr 22
Coya Therapeutics, Inc. Reports Progress from Academic Supported First-in-Class Treg-Derived Exosome ProgramMar 26
Coya Therapeutics, Inc. Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical DevelopmentFeb 07
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory DiseasesJan 22
Coya Therapeutics, Inc. Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (Ld Il-2) + Ctla4-Ig Fusion Protein in Patients with Frontotemporal Dementia (Ftd)Dec 18
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)Oct 29
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's DiseaseMay 23
Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery FoundationMay 22
Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery FoundationMay 21
Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology ConferenceMar 13
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral SclerosisJan 17
Coya Therapeutics, Inc. Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of Coya 302 for Treatment of Amyotrophic Lateral SclerosisJan 05
Coya Therapeutics, Inc. Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)Oct 10
Coya Therapeutics, Inc. Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral SclerosisOct 06
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium MeetingOct 05
Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple DiseasesSep 08
Coya Therapeutics, Inc. Reports the Publication of a Research Article Entitled “Immunological, Oxidative, and Structural Factors and Their Responses T Lymphocyte Therapy in Amyotrophic Lateral Sclerosis”Sep 01
Coya Therapeutics, Inc. Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical AdvisorJul 22
Coya Therapeutics Reports Additional Proof-Of-Concept Clinical Biomarker Data in Patients with Alzheimer's DiseaseJul 18
Coya Therapeutics, Inc. to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD)Jun 29
Coya Therapeutics, Inc. Appoints Dr. Michelle Frazier as Senior Vice President of Regulatory AffairsJun 15
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer's Disease (AD)Jun 08
Coya Therapeutics, Inc. Announces Appointment of Dr. Guillaume Dorothée to Scientific Advisory BoardJun 06
Coya Therapeutics, Inc. Reports Results from an Open-Label Proof-Of-Concept Clinical Study for COYA 301 in patients with AD. Results of the studyMay 17
Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)Jan 28
